The health ministry granted orphan-drug designation to Jazz Pharmaceuticals' cannabidiol on 6 June 2024, for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex.[1] The designation is a step before approval, and it came as Japan prepared to allow cannabis-derived medicines under the reform that took effect in December.[1]
Listed for context. No score change is recorded for Japan here.
References
Checked. The date and the event were compared with a source that was read.